Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
In the 1910s, the American Medical Association fought quackery promoted in pamphlets for drugs and treatments for everything from teething to epilepsy.
AMA J Ethics. 2018;20(11):E1082-1093. doi:
10.1001/amajethics.2018.1082.
With a focus on health justice, literature review suggests possible relationships between HPV type and geography and demonstrates that insurance status matters.
AMA J Ethics. 2019;21(3):E269-272. doi:
10.1001/amajethics.2019.269.
Dr Ala Shaikhkhalil joins Ethics Talk to discuss her article, coauthored with Drs Ethan A. Mezoff and Hannah Hays: “Should Clinicians Prescribe Non-FDA Regulated Dietary Supplements When Caring for Children With Hypovitaminosis D?”